Cargando…

FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway

Cancer stem cell-like phenotype is critical for tumor formation and treatment resistance. FGFR1 is found to be amplified in non-small cell lung cancer, particularly in the lung squamous cell cancer (LSCC). Whether FGFR1 contributes to the maintenance of stem cell-like phenotype of FGFR1-amplified lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Wenxiang, Yu, Yongfeng, Li, Ziming, Wang, Guan, Li, Fan, Xia, Weiliang, Lu, Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924774/ https://www.ncbi.nlm.nih.gov/pubmed/26936993 http://dx.doi.org/10.18632/oncotarget.7701

Ejemplares similares

Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2019)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
por: Li, Fan, et al.
Publicado: (2020)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Role of Postnatal Expression of Fgfr1 and Fgfr2 in Testicular Germ Cells on Spermatogenesis and Fertility in Mice
por: Li, Shengqiang, et al.
Publicado: (2014)

FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
por: Jang, Min Hye, et al.
Publicado: (2012)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling
por: Zhou, Siru, et al.
Publicado: (2015)

Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
por: Sawayama, Saki, et al.
Publicado: (2022)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer
por: Theelen, Willemijn SME, et al.
Publicado: (2016)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
por: Zhou, Zhen, et al.
Publicado: (2021)

MiR‐3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway
por: Kong, Shiqi, et al.
Publicado: (2020)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models()()
por: Guffanti, Federica, et al.
Publicado: (2016)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021)

Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
por: Kono, Michihisa, et al.
Publicado: (2022)

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)

Expanding the clinical phenotype of FGFR1 internal tandem duplication
por: Kautto, Esko A., et al.
Publicado: (2022)

FGFR2 loss sensitizes MYCN‐amplified neuroblastoma CHP134 cells to CHK1 inhibitor–induced apoptosis
por: Ando, Kiyohiro, et al.
Publicado: (2021)

FGFR3 has tumor suppressor properties in cells with epithelial phenotype
por: Lafitte, Marie, et al.
Publicado: (2013)

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
por: Dutt, Amit, et al.
Publicado: (2011)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival
por: Mathur, Anjili, et al.
Publicado: (2014)

βKlotho is identified as a target for theranostics in non-small cell lung cancer
por: Li, Fan, et al.
Publicado: (2019)

Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
por: Georgescu, Maria-Magdalena, et al.
Publicado: (2021)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer
por: Pandey, Gaurav, et al.
Publicado: (2019)

βKlotho is identified as a target for theranostics in non-small cell lung cancer: Erratum
por: Li, Fan, et al.
Publicado: (2023)

Addiction of mesenchymal phenotypes on the FGF/FGFR axis in oral squamous cell carcinoma cells
por: Osada, Asami Hotta, et al.
Publicado: (2019)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cfuktcrf2qnsj1k11he2olbekt